Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 3313-3316, July 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, H.
Right arrow Articles by Imai, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, H.
Right arrow Articles by Imai, K.
[Cancer Research 59, 3313-3316, July 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Association of Matrilysin Expression with Recurrence and Poor Prognosis in Human Esophageal Squamous Cell Carcinoma1

Hiroyuki Yamamoto2, Yasushi Adachi2, Fumio Itoh3, Shouhei Iku, Keiki Matsuno, Masanobu Kusano, Yoshiaki Arimura, Takao Endo, Yuji Hinoda, Masao Hosokawa and Kohzoh Imai

First Department of Internal Medicine, Sapporo Medical University, Sapporo, 060-8543 [H. Y., Y. A., F. I., S. I., K. M., M. K., Y. A., T. E., Y. H., K. I.]; and Surgery, Keiyukai Sapporo Hospital, Sapporo, 030-0027 [M. K., M. H.], Japan


   ABSTRACT
Top
 ABSTRACT
Introduction
 Patients and Methods
 Results
 Discussion
 REFERENCES
 
Matrix metalloproteinase-7 (matrilysin) has been implicated in tumor invasion and metastasis as well as tumor initiation and growth. In this study, we analyzed an association between immunohistochemically detected matrilysin expression at the invasive front in esophageal squamous cell carcinomas and clinicopathological characteristics and determined whether matrilysin predicts recurrence and/or survival. Matrilysin expression at the invasive front was detected in 49% of 100 carcinoma tissues and was associated with the depth of invasion (P < 0.0001), advanced tumor stage (P = 0.0159), recurrences (P = 0.0002), and recurrences within the first postoperative year (P = 0.002). Patients with matrilysin-positive carcinoma had a significantly shorter disease-free and overall survival time than did those with a matrilysin-negative one (P < 0.0001). Matrilysin remained a significant predictive value for disease-free and overall survival in multivariate analysis, including conventional clinicopathological factors (P = 0.0007 and 0.0004, respectively). Our results suggest that matrilysin may play a key role in the progression of esophageal carcinoma and that its detection may be useful for the prediction of recurrence and poor prognosis and, possibly, for selecting patients for anti-matrix metalloproteinase therapy.


   Introduction
Top
 ABSTRACT
 Introduction
Patients and Methods
 Results
 Discussion
 REFERENCES
 
It has become clear that cancers develop and progress through the accumulation of various genetic alterations. Esophageal carcinoma is one of the most aggressive malignant tumors, and its prognosis is still worse than that of other digestive tract cancers. Five-year overall survival after potentially curative surgical resection is still very low, due to the high rate of local and distant recurrences (1) . Although conventional pathological staging has served as the standard measure of prognosis of patients with esophageal carcinoma, it does not always define the individual risk of recurrence after surgical resection. In other words, poor prognosis of these patients is not necessarily predicted by the TNM4 classification alone. Recent advances in the molecular genetics of esophageal carcinoma have stimulated attempts to evaluate the prognostic significance of specific genetic alterations in this tumor (2 , 3) . Identification of a prognostic marker that is susceptible to or modifiable by direct therapeutic intervention will result in therapeutic and prognostic improvements for these patients.

In this regard, matrilysin, a member of the MMP family, is an engaging target for research. Matrilysin has unique characteristics, such as a minimum MMP structure, wide spectrum of substrate specificity, and a potency to start an activation cascade of MMPs (4 , 5) . In addition to the overexpression in a variety of cancer tissues (4, 5, 6, 7, 8) , in vitro and animal data suggest that matrilysin may play a key role in tumor invasion (7 , 9, 10, 11) and metastasis (12) as well as tumor initiation and growth (13, 14, 15) . Its advantage as a possible biological marker of tumor behavior is a production by cancer cells themselves. We have reported that matrilysin expression at the invasive front correlates with the progression of gastric cancers (16) . Matrilysin expression at the invasive front was also frequently observed in a small number of esophageal SCC tissues that we examined (16) . Another advantage is susceptibility to direct therapeutic intervention. Administration of a synthetic MMP inhibitor batimastat to Min mice reportedly suppresses tumor multiplicity by nearly 50%, which is similar to that observed in matrilysin-deficient Min mice (14 , 17) . Indeed, clinical trials of several synthetic MMP inhibitors are currently underway (18) . Inhibition of matrilysin by an antisense expression vector or antisense oligonucleotides has been demonstrated to suppress the in vitro invasive potential and in vivo metastatic potential of tumor cells (10 , 19 , 20) .

On the basis of these findings, we analyzed immunohistochemically matrilysin expression in 100 primary esophageal SCC tissues to determine whether matrilysin expression at the invasive front correlates with clinicopathological characteristics, disease recurrence, and survival.


   Patients and Methods
Top
 ABSTRACT
 Introduction
 Patients and Methods
Results
 Discussion
 REFERENCES
 
Patients and Tissue Samples.
Paraffin-embedded tumor specimens from 100 Japanese patients with esophageal SCC were used for immunohistochemical analysis. All patients had undergone surgical resection at Keiyukai Sapporo Hospital. The clinicopathological characteristics were evaluated according to the guidelines of the Union Internationale Contre le Cancer.

Immunohistochemistry.
The 5-mm sections were dewaxed in xylene, rehydrated in alcohol, and then heated to 105°C in an autoclave for 10 min. The endogenous peroxidase activity was suppressed by a solution of 3% hydrogen peroxide in methanol for 5 min. After being rinsed twice in PBS, the sections were treated for 18 h with an antihuman matrilysin monoclonal antibody (141-7B2; 10 µg/ml, Fuji Chemical, Toyama, Japan) diluted in PBS (21) . After washing three times in PBS, the sections were treated with biotinylated goat antimouse immunoglobulin (DAKO, Glostrup, Denmark) for 10 min, followed by horseradish peroxidase-avidin complex, diluted as recommended by the manufacturer (DAKO) for 10 min. The slides were then washed in PBS and developed in 0.05 M Tris-HCl (pH 7.5) containing 0.6 mg/ml 3,3'-diaminobenzidine at room temperature. The sections were counterstained in Mayer’s hematoxylin and mounted. Immunostaining signals at the invasive front were scored in two sections each by two independent observers. The scores were calculated as the number of stained cells divided by the total number of carcinoma cells, as described previously (22) . Cases were considered positive when >30% of carcinoma cells at the invasive front were stained with the antibody.

Statistical Analysis.
Matrilysin expression was assessed for associations with clinicopathological parameters using following statistical tests: Student’s t test for age, Mann-Whitney U test for the depth of invasion and TNM stage, and {chi}2 two-tailed test for the remaining parameters. Survival analysis was carried out excluding patients with noncurative operation or who died other than carcinoma, leaving 90 patients for analysis. Probability distributions of disease-free and overall survival were calculated using the Kaplan-Meier method and compared by the log-rank test. The Cox model was used for univariate and multivariate analyses. A P of <0.05 was considered significant.


   Results
Top
 ABSTRACT
 Introduction
 Patients and Methods
 Results
Discussion
 REFERENCES
 
Fig. 1Citation shows representative results of immunohistochemistry for matrilysin in esophageal SCC tissues. The cytoplasm and cell membrane of carcinoma cells were stained for matrilysin, but stromal cells other than some monocytes were not stained. There was no detectable immunoreactivity with the control AI-206 antibody (data not shown). Sections with immunostaining signals in >30% of carcinoma cells at the invasive front were judged as being positive for matrilysin, which was thus observed in 49% of 100 cases. The relationship between the expression of matrilysin and clinicopathological characteristics is listed in Table 1Citation . The expression of matrilysin was associated with the depth of invasion (P < 0.0001), advanced tumor stage (P = 0.0159), recurrences (P = 0.0002), and recurrences within the first postoperative year (P = 0.002). On the other hand, there were no significant relationships between matrilysin expression and age, sex, lymph node, or distant metastasis (Table 1Citation and data not shown).



View larger version (93K):
[in this window]
[in a new window]
  		Fig. 1. Immunohistochemistry of matrilysin in esophageal SCC tissues. A, matrilysin-positive SCC (x40). B, higher magnification of A (x200). C, matrilysin-negative SCC (x 200).

 

View this table:
[in this window]
[in a new window]
  		Table 1 Association of matrilysin expression with clinicopathological characteristics

 
Patients with matrilysin-positive carcinoma had significantly shorter disease-free (P < 0.0001) and overall (P < 0.0001) survival times than did those with matrilysin-negative carcinoma (Fig. 2)Citation . In the univariate analysis, significant prognostic variables for predicting both disease-free and overall survival were matrilysin expression, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage (Table 2)Citation . In the multivariate analysis of these variables, only matrilysin remained a significant prognostic variable for predicting disease-free and overall survival (Table 2)Citation .



View larger version (19K):
[in this window]
[in a new window]
  		Fig. 2. Kaplan-Meier disease-free (A) and overall (B) survival curves of patients with esophageal SCC according to the expression of matrilysin at the invasive front.

 

View this table:
[in this window]
[in a new window]
  		Table 2 Univariate and multivariate analyses of disease-free and overall survival

 

   Discussion
Top
 ABSTRACT
 Introduction
 Patients and Methods
 Results
 Discussion
REFERENCES
 
In this study, matrilysin expression in carcinoma cells at the invasive front was immunohistochemically seen in 49% of patients with esophageal SCC and was associated with the depth of invasion and advanced tumor stage. Thus, matrilysin at the invasive front is likely to contribute to the more invasive phenotype of carcinoma cells, resulting in the progression of esophageal SCC.

The implication of matrilysin expression at the invasive front was further substantiated by its correlation with disease recurrence and shorter disease-free and overall survival time. Moreover, only matrilysin provided a significant predictive value for disease-free and overall survival in the multivariate analysis, suggesting that matrilysin expression could be a powerful predictor of recurrence and poor prognosis, with a significance equaling or surpassing other conventional clinicopathological factors.

Identification of matrilysin as a molecular marker that correlates with disease recurrence and poor prognosis would provide new insights into disease management by making it possible to define a high risk of recurrence, thus providing a more accurate estimation of prognosis of patients with esophageal SCC. Consequently, early postoperative screening and/or intense postoperative therapy should be performed on patients with matrilysin-positive carcinoma. Immunohistochemical analysis is a technique that is feasible in daily clinical practice, and therefore, analysis of matrilysin expression could be an important routine part of the management of patients with esophageal SCC.

Nevertheless, the effect of conventional therapy may be limited for patients with high malignant potential such as those with matrilysin-positive carcinoma. Indeed, several attempts have been made to try to develop a novel therapeutic approach. In this regard, it is noteworthy that matrilysin could be a potential target for therapeutic intervention. The use of synthetic broad-spectrum MMP inhibitors is one of possible strategies (18) . Considering our results, matrilysin could be a primary target of such inhibitors in esophageal SCC. Although considerable optimization is necessary in many aspects, the use of matrilysin-specific antisense oligonucleotides may be another possibility in the future (10 , 19 , 20) . Thus, the immunohistochemical analysis of matrilysin in esophageal SCC tissues could also form the basis of a new therapeutic strategy via broad and/or selective MMP inhibitors. The diagnostic strategy shown in this study and the advances in therapeutic approaches would improve the prognosis of patients with esophageal SCC.


   FOOTNOTES
 
1 Supported by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture (to F. I., Y. H., and K. I.) and from the Ministry of Health and Welfare (to F. I., Y. H., and K. I.), Tokyo, Japan. Back

2 The first two authors contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at First Department of Internal Medicine, Sapporo Medical University, South-1, West-16, Chuo-ku, Sapporo 060-8543, Japan. Phone: 81-11-611-2111; Fax: 81-11-613-1141. Back

4 The abbreviations used are: TNM, tumor-node-metastasis; MMP, matrix metalloproteinase; SCC, squamous cell carcinoma. Back

Received 4/14/99. Accepted 5/27/99.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Patients and Methods
 Results
 Discussion
 REFERENCES
 

  1. Sagar P. M., Gauperaa T., Sue-Ling H. S., McMahon M. J., Johnston D. An audit of the treatment of cancer of the esophagus. Gut, 35: 941-945, 1994.[Abstract/Free Full Text]
  2. Naitoh H., Shibata J., Kawaguchi A., Kodama M., Hattori T. Overexpression and localization of cyclin D1 mRNA and antigen in esophageal cancer. Am. J. Pathol., 146: 1161-1169, 1995.[Abstract]
  3. Kitagawa Y., Ueda M., Ando N., Ozawa S., Shimizu N., Kitajima M. Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma. Clin. Cancer Res., 2: 909-914, 1996.[Abstract]
  4. Wilson C. L., Matrisian L. M. Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int. J. Biochem. Cell Biol., 28: 123-136, 1996.[Medline]
  5. Wilson C. L., Matrisian L. M. Matrilysin Parks W. C. Mecham R. P. eds. . Matrix Metalloproteinases, : 149-184, Academic Press San Diego 1998.
  6. Yamamoto H., Itoh F., Adachi Y., Sakamoto H., Adachi M., Hinoda Y., Imai K. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology, 112: 1271-1277, 1997.[Medline]
  7. Senota A., Itoh F., Yamamoto H., Adachi Y., Hinoda Y., Imai K. Relation of matrilysin messenger RNA expression with invasive activity in human gastric cancer. Clin. Exp. Metastasis, 16: 313-321, 1998.[Medline]
  8. Yamamoto H., Itoh F., Adachi Y., Fukushima H., Itoh H., Sasaki S., Hinoda Y., Imai K. Messenger RNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human hepatocellular carcinoma. Jpn. J. Clin. Oncol., 29: 58-62, 1999.[Abstract/Free Full Text]
  9. Powell W. C., Knox J. D., Navre M., Grogan T. M., Kittelson J., Nagle R. B., Bowden G. T. Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice. Cancer Res., 53: 417-422, 1993.[Abstract/Free Full Text]
  10. Yamamoto H., Itoh F., Hinoda Y., Imai K. Suppression of matrilysin inhibits colon cancer cell invasion in vitro. Int. J. Cancer, 61: 218-222, 1995.[Medline]
  11. Itoh F., Yamamoto H., Hinoda Y., Imai K. Enhanced secretion and activation of matrilysin during malignant conversion of human colorectal epithelium and its relationship with invasive potential of colon cancer cells. Cancer (Phila.), 77: 1717-1721, 1996.[Medline]
  12. Adachi, Y., Yamamoto, H., Itoh, F., Hinoda, Y., Okada, Y., and Imai, K. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut, in press, 1999.
  13. Witty J. P., McDonell S., Newell K., Cannon P., Navre M., Tressler R., Matrisian L. M. Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res., 54: 4805-4812, 1994.[Abstract/Free Full Text]
  14. Wilson C. L., Heppner K. J., Labosky P. A., Hogan B. L., Matrisian L. M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc. Natl. Acad. Sci. USA, 94: 1402-1407, 1997.[Abstract/Free Full Text]
  15. Rudolph-Owen L. A., Chan R., Muller W. J., Matrisian L. M. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis. Cancer Res., 58: 5500-5506, 1998.[Abstract/Free Full Text]
  16. Adachi Y., Itoh F., Yamamoto H., Matsuno K., Arimura Y., Kusano M., Endoh T., Hinoda Y., Oohara M., Hosokawa M., Imai K. Matrix metalloproteinase matrilysin (MMP-7) participates in the progression of human gastric and esophageal cancers. Int. J. Oncol., 13: 1031-1035, 1998.[Medline]
  17. Goss K. J. H., Brown P. D., Matrisian L. M. Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int. J. Cancer, 78: 629-635, 1998.[Medline]
  18. Nemunaitis J., Poole C., Primrose J., Rosemurgy A., Malfetano J., Brown P., Berrington A., Cornish A., Lynch K., Rasmussen H., Kerr D., Cox D., Millar A. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin. Cancer Res., 4: 1101-1109, 1998.[Abstract]
  19. Hasegawa S., Koshikawa N., Momiyama N., Moriyama K., Ichikawa Y., Ishikawa T., Mitsuhashi M., Shimada H., Miyazaki K. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int. J. Cancer, 76: 812-816, 1998.[Medline]
  20. Momiyama N., Koshikawa N., Ishikawa T., Ichikawa Y., Hasegawa S., Nagashima Y., Mitsuhashi M., Miyazaki K., Shimada H. Inhibitory effect of matrilysin antisense oligonucleotides on human colon cancer cell invasion in vitro. Mol. Carcinog., 22: 57-63, 1998.[Medline]
  21. Ohuchi E., Azumano I., Yoshida S., Iwata K., Okada Y. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 7 (matrilysin) using monoclonal antibodies. Clin. Chim. Acta, 244: 181-198, 1996.[Medline]
  22. Kawano N., Osawa H., Ito T., Nagashima Y., Hirahara F., Inayama Y., Nakatani Y., Kimura S., Kitajima H., Koshikawa N., Miyazaki K., Kitamura H. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin(ogen) in lung neoplasms: an immunohistochemical study. Hum. Pathol., 28: 613-622, 1997.[Medline]



This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Yokoyama, F. Grunebach, S. M. Schmidt, A. Heine, M. Hantschel, S. Stevanovic, H.-G. Rammensee, and P. Brossart
Matrilysin (MMP-7) Is a Novel Broadly Expressed Tumor Antigen Recognized by Antigen-Specific T Cells
Clin. Cancer Res., September 1, 2008; 14(17): 5503 - 5511.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
A. Imsumran, Y. Adachi, H. Yamamoto, R. Li, Y. Wang, Y. Min, W. Piao, K. Nosho, Y. Arimura, Y. Shinomura, et al.
Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma
Carcinogenesis, May 1, 2007; 28(5): 947 - 956.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
Y. Miyata, T. Iwata, K. Ohba, S. Kanda, M. Nishikido, and H. Kanetake
Expression of Matrix Metalloproteinase-7 on Cancer Cells and Tissue Endothelial Cells in Renal Cell Carcinoma: Prognostic Implications and Clinical Significance for Invasion and Metastasis
Clin. Cancer Res., December 1, 2006; 12(23): 6998 - 7003.
[Abstract] [Full Text] [PDF]

Home page
 Exp. Biol. Med.Home page
M. Ii, H. Yamamoto, Y. Adachi, Y. Maruyama, and Y. Shinomura
Role of Matrix Metalloproteinase-7 (Matrilysin) in Human Cancer Invasion, Apoptosis, Growth, and Angiogenesis
Experimental Biology and Medicine, January 1, 2006; 231(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
S Kurokawa, Y Arimura, H Yamamoto, Y Adachi, T Endo, T Sato, T Suga, M Hosokawa, Y Shinomura, and K Imai
Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers
Gut, December 1, 2005; 54(12): 1751 - 1758.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, P. Bernardo, P. Stephenson, W. J. Gradishar, J. N. Ingle, S. Zucker, and N. E. Davidson
Randomized Phase III Trial of Marimastat Versus Placebo in Patients With Metastatic Breast Cancer Who Have Responding or Stable Disease After First-Line Chemotherapy: Eastern Cooperative Oncology Group Trial E2196
J. Clin. Oncol., December 1, 2004; 22(23): 4683 - 4690.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. A. Sparano, R. Gray, B. Giantonio, P. O'Dwyer, and R. L. Comis
Evaluating Antiangiogenesis Agents in the Clinic: The Eastern Cooperative Oncology Group Portfolio of Clinical Trials
Clin. Cancer Res., February 15, 2004; 10(4): 1206 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Endo, T. Takino, H. Miyamori, H. Kinsen, T. Yoshizaki, M. Furukawa, and H. Sato
Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration
J. Biol. Chem., October 17, 2003; 278(42): 40764 - 40770.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. V. S. Kallakury, S. Karikehalli, A. Haholu, C. E. Sheehan, N. Azumi, and J. S. Ross
Increased Expression of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitors of Metalloproteinases 1 and 2 Correlate with Poor Prognostic Variables in Renal Cell Carcinoma
Clin. Cancer Res., October 1, 2001; 7(10): 3113 - 3119.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Hoekstra, F.A.L.M. Eskens, and J. Verweij
Matrix Metalloproteinase Inhibitors: Current Developments and Future Perspectives
Oncologist, October 1, 2001; 6(5): 415 - 427.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Fukushima, H. Yamamoto, F. Itoh, H. Nakamura, Y. Min, S. Horiuchi, S. Iku, S. Sasaki, and K. Imai
Association of matrilysin mRNA expression with K-ras mutations and progression in pancreatic ductal adenocarcinomas
Carcinogenesis, July 1, 2001; 22(7): 1049 - 1052.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Yamamoto, F. Itoh, S. Iku, M. Hosokawa, and K. Imai
Expression of the {{gamma}}2 Chain of Laminin-5 at the Invasive Front Is Associated with Recurrence and Poor Prognosis in Human Esophageal Squamous Cell Carcinoma
Clin. Cancer Res., April 1, 2001; 7(4): 896 - 900.
[Abstract] [Full Text]

Home page
 JCOHome page
H. Yamamoto, F. Itoh, S. Iku, Y. Adachi, H. Fukushima, S. Sasaki, M. Mukaiya, K. Hirata, and K. Imai
Expression of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Human Pancreatic Adenocarcinomas: Clinicopathologic and Prognostic Significance of Matrilysin Expression
J. Clin. Oncol., February 15, 2001; 19(4): 1118 - 1127.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
M. Hidalgo and S. G. Eckhardt
Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy
J Natl Cancer Inst, February 7, 2001; 93(3): 178 - 193.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Mitsiades, W.-h. Yu, V. Poulaki, M. Tsokos, and I. Stamenkovic
Matrix Metalloproteinase-7-mediated Cleavage of Fas Ligand Protects Tumor Cells from Chemotherapeutic Drug Cytotoxicity
Cancer Res., January 1, 2001; 61(2): 577 - 581.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
I. Ozaki, T. Mizuta, G. Zhao, H. Yotsumoto, T. Hara, S. Kajihara, A. Hisatomi, T. Sakai, and K. Yamamoto
Involvement of the Ets-1 Gene in Overexpression of Matrilysin in Human Hepatocellular Carcinoma
Cancer Res., November 1, 2000; 60(22): 6519 - 6525.
[Abstract] [Full Text]

Home page
 JCOHome page
A. R. Nelson, B. Fingleton, M. L. Rothenberg, and L. M. Matrisian
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
J. Clin. Oncol., March 1, 2000; 18(5): 1135 - 1135.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Yamashita, M. Mori, T. Shiraishi, K. Shibuta, and K. Sugimachi
Clinical Significance of Matrix Metalloproteinase-7 Expression in Esophageal Carcinoma
Clin. Cancer Res., March 1, 2000; 6(3): 1169 - 1174.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yamamoto, H.
Right arrow Articles by Imai, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yamamoto, H.
Right arrow Articles by Imai, K.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online